GlassScriptPhysician profile
Gary A Koenig
NPI 1942204656
$4,378.61
in general payments reported to CMS, 2019-2025
35 companies · $485 in 2025
The $485 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $237 · 2021: $360 · 2022: $626 · 2023: $1,130 · 2024: $1,031 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.21 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $789.84 | 2021-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.99 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $355.06 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Grifols USA, LLC | $321.16 | 2019-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $219.45 | 2021-2024 | Xywav |
| Amgen INC. | $204.34 | 2022-2025 | Tezspire, Tavneos |
| United Therapeutics Corporation | $185.14 | 2019-2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $183.25 | 2019-2025 | Uptravi, Opsumit |
| Genentech USA, INC. | $166.78 | 2019-2022 | |
| Glaxosmithkline, LLC. | $157.67 | 2019-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $133.38 | 2021-2025 | Glassia, Aralast |
| Itamar Medical INC | $114.62 | 2021-2022 | |
| Genzyme Corporation | $114.25 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.05 | 2022-2024 | |
| Philips North America LLC | $95.20 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $94.96 | 2023-2025 | Lumryz |
| Insmed, INC. | $87.08 | 2019-2024 | Arikayce |
| Pulmonx Corporation | $85.46 | 2022 | |
| Csl Behring | $85.11 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $72.15 | 2021-2025 | Dupixent |
| Axsome Therapeutics, INC. | $56.18 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $48.79 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $39.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $32.62 | 2023 | Acthar |
| Azurity Pharmaceuticals, INC. | $30.34 | 2024 | Horizant |
| Gilead Sciences, INC. | $23.30 | 2021 | |
| Pharming Healthcare, INC. | $21.09 | 2022 | |
| Merck Sharp & Dohme LLC | $18.48 | 2022 | |
| Lilly USA, LLC | $18.05 | 2025 | Zepbound |
| Zoll Respicardia, INC. | $16.82 | 2024 | Remede System |
| Baxter Healthcare | $16.28 | 2022 | |
| Electromed, INC. | $15.62 | 2021 | |
| Applied Medical Technology INC | $14.37 | 2023 | Amt Bridle Pro |
| Vifor Pharma, INC. | $14.26 | 2024 | Zemaira |
| Novartis Pharmaceuticals Corporation | $13.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Koenig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.